Douglas Lane & Associates LLC Has $82.27 Million Stock Holdings in Haleon plc (NYSE:HLN)

Douglas Lane & Associates LLC lifted its holdings in shares of Haleon plc (NYSE:HLN - Free Report) by 1.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,624,149 shares of the company's stock after buying an additional 161,865 shares during the period. Haleon comprises 1.2% of Douglas Lane & Associates LLC's holdings, making the stock its 23rd largest position. Douglas Lane & Associates LLC owned approximately 0.19% of Haleon worth $82,274,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of HLN. AE Wealth Management LLC increased its stake in shares of Haleon by 6.1% during the 2nd quarter. AE Wealth Management LLC now owns 19,199 shares of the company's stock worth $159,000 after purchasing an additional 1,098 shares during the last quarter. Lake Street Advisors Group LLC grew its holdings in Haleon by 5.4% during the third quarter. Lake Street Advisors Group LLC now owns 22,395 shares of the company's stock worth $237,000 after purchasing an additional 1,143 shares during the period. Synovus Financial Corp raised its stake in Haleon by 0.8% in the third quarter. Synovus Financial Corp now owns 148,834 shares of the company's stock valued at $1,575,000 after buying an additional 1,216 shares during the period. Hexagon Capital Partners LLC lifted its position in shares of Haleon by 18.5% in the third quarter. Hexagon Capital Partners LLC now owns 7,933 shares of the company's stock valued at $84,000 after buying an additional 1,238 shares during the last quarter. Finally, Brown Brothers Harriman & Co. boosted its stake in shares of Haleon by 21.4% during the 2nd quarter. Brown Brothers Harriman & Co. now owns 7,569 shares of the company's stock worth $63,000 after acquiring an additional 1,334 shares during the period. Institutional investors own 6.67% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Sanford C. Bernstein cut Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday. UBS Group raised shares of Haleon to a "strong-buy" rating in a research report on Tuesday, October 1st. Finally, Morgan Stanley lifted their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an "overweight" rating in a report on Friday, September 20th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $10.95.

Haleon Stock Performance

NYSE HLN traded up $0.04 on Wednesday, reaching $9.50. The stock had a trading volume of 11,082,673 shares, compared to its average volume of 7,514,995. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company has a market cap of $43.00 billion, a P/E ratio of 27.94, a price-to-earnings-growth ratio of 2.95 and a beta of 0.29. The firm has a fifty day moving average of $9.61 and a two-hundred day moving average of $9.67. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.